Abstract Body

Background: WHO recommends cotrimoxazole (CTX) prophylaxis for children born to HIV-infected mothers from 6 weeks of age until breastfeeding cessation and exclusion of HIV infection. We report on the protective efficacy and safety of CTX prophylaxis in these children when continued beyond breastfeeding cessation to age 4. Methodology: We conducted an open-label randomized controlled trial alongside two observational cohorts in Eastern Uganda, an area of high HIV prevalence, malaria transmission intensity, and antifolate-resistance. 203 HIV-exposed infants enrolled between 6 weeks and 9 months of age were prescribed daily CTX until breastfeeding cessation and HIV status confirmation. After breastfeeding ended, 185 children remained in active follow-up and HIV-uninfected and were randomized 1:1 to discontinue or continue CTX prophylaxis until age 2 years. At that age, the 91 children who continued CTX were randomized 1:1 again to continue or discontinue CTX from age 2 through age 4. For additional comparisons, 48 HIV-infected children on continuous CTX prophylaxis and 100 HIV-unexposed uninfected children who never received CTX prophylaxis were enrolled. All children were followed to age 5. Main outcome measures included malaria incidence, grade 3 and 4 serious adverse events (SAEs), and hospitalizations. Results: Out of the 185 HIV-exposed children who remained enrolled and HIV-uninfected after the end of breastfeeding, 152 (82.2%) and 146 (78.9%) randomized HIV-exposed children were followed to age 4 and 5 respectively. Continuing CTX prophylaxis to age 4 yielded a 43% reduction in malaria (incidence rate ratio, 0.57; 95% CI, 0.49-0.66; p<0.001). Throughout follow-up, malaria incidence was lowest among HIV-infected children who received continuous CTX prophylaxis and highest among HIV-negative unexposed children who never received CTX prophylaxis. There were no significant differences in incidence of grade 3 or 4 SAEs, hospitalizations, or deaths among HIV-exposed, HIV-unexposed, and HIV-infected children. There was no evidence of malaria incidence rebound in the year following discontinuation of CTX at age 2 or 4, but incidence increased significantly from age 4 to 5 among children who stopped CTX at age 4. Conclusions: These results indicate that continuing cotrimoxazole prophylaxis beyond the period recommended by WHO is safe and efficacious in protecting HIV-exposed children living in malaria endemic areas even in the presence of high anti-folate resistance.